Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension

American Journal of Hypertension

Volumn 28, Issue 9, 2015, Pages 1083-1090

  Lincevicius, Gisele S ^a   Shimoura, Caroline G ^a   Nishi, Erika E ^a   Perry, Juliana C ^a   Casarini, Dulce E ^a   Gomes, Guiomar N ^a   Bergamaschi, Cássia T ^a   Campos, Ruy R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

baroreflex dysfunction; blood pressure; hypertension; renal injury; renin angiotensin aldosterone; renovascular hypertension; sympathoexcitation

Indexed keywords

ALDOSTERONE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; KIDNEY RENIN; POTASSIUM; RENIN; SPIRONOLACTONE; URETHAN; WATER; ACTIN; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST; SMOOTH MUSCLE ACTIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANDROGEN THERAPY; ARTICLE; CONTROLLED STUDY; EXCITATION; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NERVE EXCITABILITY; NONHUMAN; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENOVASCULAR HYPERTENSION; SYMPATHETIC NERVE; SYMPATHOEXCITATION; URINE VOLUME; ADRENERGIC SYSTEM; ANIMAL; ARTERIAL PRESSURE; BLOOD; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, RENOVASCULAR; INNERVATION; KIDNEY; MEDULLA OBLONGATA; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WISTAR RAT;

ACTINS; ALDOSTERONE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; BAROREFLEX; DISEASE MODELS, ANIMAL; HEART RATE; HYPERTENSION, RENOVASCULAR; KIDNEY; MALE; MEDULLA OBLONGATA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; SYMPATHETIC NERVOUS SYSTEM;

EID: 84940763035     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu300     Document Type: Article

References (42)

1. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011:236239.
2. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998; 13:170-176.
3. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 1991; 17:707-719.
4. de Oliveira-Sales EB, Nishi EE, Boim MA, Dolnikoff MS, Bergamaschi CT, Campos RR. Upregulation of AT1R and iNOS in the rostral ventrolateral medulla (RVLM) is essential for the sympathetic hyperactivity and hypertension in the 2K-1C Wistar rat model. Am J Hypertens 2010; 23:708-715.
5. Campos RR, Oliveira-Sales EB, Nishi EE, Boim MA, Dolnikoff MS, Bergamaschi CT. The role of oxidative stress in renovascular hypertension. Clin Exp Pharmacol Physiol 2011; 38:144-152.
6. Nishi EE, Oliveira-Sales EB, Bergamaschi CT, Cesar Oliveira TG, Boim MA, Campos RR: Chronic antioxidant treatment improves arterial renovascular hypertension and oxidative stress markers in the kidney in Wistar rats. Am J Hypertens 2010; 23:473-480.
7. Pradhan N, Rossi NF. Interactions between the sympathetic nervous system and angiotensin system in renovascular hypertension. Curr Hypertens Rev 2013; 9:121-129.
8. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008; 294:H1067-H1074.
9. Lemarié CA, Simeone SM, Nikonova A, Ebrahimian T, Deschênes ME, Coffman TM, Paradis P, Schiffrin EL. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009; 105:852-859.
10. Xue B, Beltz TG, Yu Y, Guo F, Gomez-Sanchez CE, Hay M, Johnson AK. Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2011; 300:H555-H564.
11. Xue B, Zhang Z, Johnson RF, Johnson AK. Sensitization of slow pressor angiotensin II (Ang II)-initiated hypertension: induction of sensitization by prior Ang II treatment. Hypertension 2012; 59:459-466.
12. Xue B, Zhang Z, Roncari CF, Guo F, Johnson AK. Aldosterone acting through the central nervous system sensitizes angiotensin II-induced hypertension. Hypertension 2012; 60:1023-1030.
13. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33:981-986.
14. Klar J, Vitzthum H, Kurtz A. Aldosterone enhances renin gene expression in juxtaglomerular cells. Am J Physiol Renal Physiol 2004; 286:F349-F355.
15. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M, Hirata Y. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 2007; 148:1688-1696.
16. Zhang ZH, Yu Y, Wei SG, Felder RB. Aldosterone-induced brain MAPK signaling and sympathetic excitation are angiotensin II type-1 receptor dependent. Am J Physiol Heart Circ Physiol 2012; 302:H742-H751.
17. Mazzocchi G, Gottardo G, Macchi V, Malendowicz LK, Nussdorfer GG. The AT2 receptor-mediated stimulation of adrenal catecholamine release may potentiate the AT1 receptor-mediated aldosterone secretagogue action of angiotensin-II in rats. Endocr Res 1998; 24:17-28.
18. Pechanova O, Matuskova J, Capikova D, Jendekova L, Paulis L, Simko F. Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats. Kidney Int 2006; 70:170-176.
19. Fredline VF, Kovacs EM, Taylor PJ, Johnson AG. Measurement of plasma renin activity with use of HPLC-electrospray-tandem mass spectrometry. Clin Chem 1999; 45:659-664.
20. Perry JC, Bergamaschi CT, Campos RR, Silva AM, Tufik S. Interconnectivity of sympathetic and sleep networks is mediated through reduction of gamma aminobutyric acidergic inhibition in the paraventricular nucleus. J Sleep Res 2014; 23:168-175.
21. Johnson CW. Issues in immunohistochemistry. Toxicol Pathol 1999; 27:246-248.
22. Rabito SF, Carretero OA, Scicli AG. Evidence against a role of vasopressin in the maintenance of high blood pressure in mineralocorticoid and renovascular hypertension. Hypertension 1981; 3:34-38.
23. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K, Ichikawa S, Matsumoto N, Sato Y, Kurabayashi M. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. Int J Cardiol 2013; 167:244-249.
24. Huang BS, Leenen FH. Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol Heart Circ Physiol 2005; 288:H2491-H2497.
25. Gómez-Sánchez EP, Zhou M, Gomez-Sanchez CE. Mineralocorticoids, salt and high blood pressure. Steroids 1996; 61:184-188.
26. Gómez-Sánchez EP. Central hypertensive effects of aldosterone. Front Neuroendocrinol 1997; 18:440-462.
27. Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Vongpatanasin W. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012; 60:319-325.
28. Drobysheva A, Ahmad M, White R, Wang HW, Leenen FH. Cardiac sympathetic innervation and PGP9.5 expression by cardiomyocytes after myocardial infarction: effects of central MR blockade. Am J Physiol Heart Circ Physiol 2013; 305:H1817-H1829.
29. McAllen RM, May CN, Campos RR. The supply of vasomotor drive to individual classes of sympathetic neuron. Clin Exp Hypertens 1997; 19:607-618.
30. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24:571-575.
31. Monahan KD, Leuenberger UA, Ray CA. Aldosterone impairs baroreflex sensitivity in healthy adults. Am J Physiol Heart Circ Physiol 2007; 292:H190-H197.
32. Haywood JR, Fink GD, Buggy J, Boutelle S, Johnson AK, Brody MJ. Prevention of two-kidney, one-clip renal hypertension in rat by ablation of AV3V tissue. Am J Physiol 1983; 245:H683-H689.
33. He DH, Zhang LM, Lin LM, Ning RB, Wang HJ, Xu CS, Lin JX. Longterm prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. Int J Mol Med 2014; 33:301-309.
34. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13:9-20.
35. Prieto-Carrasquero MC, Botros FT, Pagan J, Kobori H, Seth DM, Casarini DE, Navar LG. Collecting duct renin is upregulated in both kidneys of 2-kidney, 1-clip Goldblatt hypertensive rats. Hypertension 2008; 51:1590-1596.
36. Sadjadi J, Puttaparthi K, Welborn MB 3rd, Rogers TE, Moe O, Clagett GP, Turnage RH, Levi M, Modrall JG. Upregulation of autocrine-paracrine renin-angiotensin systems in chronic renovascular hypertension. J Vasc Surg 2002; 36:386-392.
37. Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Schäfers HJ, Böhm M, Laufs U. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 2014; 289:6656-6668.
38. Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol 2014; 34:355-364.
39. Vazquez-Rangel A, Soto V, Escalona M, Toledo RG, Castillo EA, Polanco Flores NA, Falcon-Chavez I, Madero M. Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial. Am J Kidney Dis 2014; 63:1072-1074.
40. Nielsen FT, Jensen BL, Hansen PB, Marcussen N, Bie P. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BMC Nephrol 2013; 14:42.
41. Montes E, Ruiz V, Checa M, Maldonado V, Melendez-Zajgla J, Montaño M, Ordoñez-Razo R, Cisneros J, García-de-Alba C, Pardo A, Selman M. Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis. Eur Respir J 2012; 39:141-148.
42. Gross O, Girgert R, Rubel D, Temme J, Theissen S, Müller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 2011; 24:355-361.